iCo Therapeutics Inc (CVE:ICO) was up 20% on Monday . The company traded as high as C$0.06 and last traded at C$0.06. Approximately 497,300 shares were traded during trading, an increase of 121% from the average daily volume of 225,309 shares. The stock had previously closed at C$0.05.
The firm has a market cap of $4.37 million and a price-to-earnings ratio of -3.00.
WARNING: This piece of content was originally reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.modernreaders.com/news/2019/02/13/ico-therapeutics-ico-trading-up-20.html.
About iCo Therapeutics (CVE:ICO)
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.